JP2008513469A - アンドロゲン除去によって生じる骨粗鬆症の治療 - Google Patents

アンドロゲン除去によって生じる骨粗鬆症の治療 Download PDF

Info

Publication number
JP2008513469A
JP2008513469A JP2007532470A JP2007532470A JP2008513469A JP 2008513469 A JP2008513469 A JP 2008513469A JP 2007532470 A JP2007532470 A JP 2007532470A JP 2007532470 A JP2007532470 A JP 2007532470A JP 2008513469 A JP2008513469 A JP 2008513469A
Authority
JP
Japan
Prior art keywords
patient
bone
toremifene
pharmaceutically acceptable
estrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007532470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513469A5 (enExample
Inventor
ステイナー、ミッチェル・エス
ベベルカ、カレン・エイ
ラゴウ、シャラン
Original Assignee
ジーティーエックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーティーエックス・インコーポレイテッド filed Critical ジーティーエックス・インコーポレイテッド
Publication of JP2008513469A publication Critical patent/JP2008513469A/ja
Publication of JP2008513469A5 publication Critical patent/JP2008513469A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2007532470A 2004-09-20 2005-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療 Pending JP2008513469A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/944,465 US20050080143A1 (en) 2001-11-29 2004-09-20 Treatment of androgen-deprivation induced osteoporosis
PCT/US2005/032998 WO2006033979A1 (en) 2004-09-20 2005-09-19 Treatment of androgen - deprivation induced osteoporosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008240566A Division JP2009029823A (ja) 2004-09-20 2008-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療

Publications (2)

Publication Number Publication Date
JP2008513469A true JP2008513469A (ja) 2008-05-01
JP2008513469A5 JP2008513469A5 (enExample) 2010-04-22

Family

ID=36090335

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007532470A Pending JP2008513469A (ja) 2004-09-20 2005-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療
JP2008240566A Pending JP2009029823A (ja) 2004-09-20 2008-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008240566A Pending JP2009029823A (ja) 2004-09-20 2008-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療

Country Status (12)

Country Link
US (1) US20050080143A1 (enExample)
EP (2) EP1935415A3 (enExample)
JP (2) JP2008513469A (enExample)
KR (1) KR20070059167A (enExample)
CN (2) CN101961327A (enExample)
AU (1) AU2005287113B2 (enExample)
BR (1) BRPI0515668A (enExample)
CA (1) CA2581159A1 (enExample)
EA (1) EA014309B1 (enExample)
IL (1) IL182091A0 (enExample)
MX (1) MX2007003272A (enExample)
WO (1) WO2006033979A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
CN116869944A (zh) * 2023-08-15 2023-10-13 重庆士立德医药科技有限公司 一种托瑞米芬组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047504A2 (en) * 2001-11-29 2003-06-12 Gtx Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
WO2004096259A1 (en) * 2003-04-30 2004-11-11 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
US2465505A (en) 1944-12-05 1949-03-29 Hoffmann La Roche Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
GB8508404D0 (en) * 1985-03-30 1985-05-09 Baylor College Medicine Therapeutic compositions
US4897254A (en) * 1984-09-21 1990-01-30 The Dow Chemical Company Radioactive compositions for the treatment of calcific tumors
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
FR2578113B1 (fr) * 1985-02-25 1988-04-15 Merlin Gerin Declencheur statique numerique a fonctions optionnelles pour un disjoncteur electrique
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
DK0595796T3 (da) * 1989-07-07 2003-05-05 Endorech Inc Fremgangsmåde til behandling af androgen-relaterede sygdomme
US5153622A (en) * 1989-08-03 1992-10-06 Asahi Kogaku Kogyo Kabushiki Kaisha Pressure alarm for water-sealed camera
JPH06287885A (ja) * 1991-04-15 1994-10-11 Yamauchi Corp 脱水プレス用エンドレスベルト
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
TW303299B (enExample) * 1993-07-22 1997-04-21 Lilly Co Eli
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
EP0891421A4 (en) * 1996-03-18 2001-07-25 Univ Pennsylvania BIOACTIVE SUBSTRATE MATERIAL FOR IMPROVED CELLULAR FIXATION AND FUNCTION
GB9712086D0 (en) * 1997-06-10 1997-08-13 Bp Chem Int Ltd Process for preparing polyketones
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
SI1003496T1 (en) * 1998-05-07 2005-10-31 The University Of Tennessee Research Corporation Medicament for treating prostate intraepithelial neoplasia
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6410043B1 (en) * 1998-05-07 2002-06-25 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
ATE315033T1 (de) * 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
US6165504A (en) * 1998-09-23 2000-12-26 Barr Laboratories, Inc. Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients
US6258802B1 (en) * 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
EP1251855A1 (en) * 2000-01-28 2002-10-30 Endorecherche, Inc. Selective estrogen receptor modulators in combination with estrogens
US6855703B1 (en) * 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
WO2001091744A1 (en) * 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
HUP0303172A3 (en) * 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
AU2001271163A1 (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
EP1210951B1 (en) * 2000-11-30 2005-02-02 Pfizer Products Inc. Composition containing estrogen agonists/antagonists and testosterone for treating a decline in the level of the hormone testosterone
US6413633B1 (en) * 2001-04-18 2002-07-02 Francis Patrick McCullough Activated biregional fiber(s)
US6838584B2 (en) * 2001-05-10 2005-01-04 Merck & Co., Inc. Estrogen receptor modulators
DE02726901T1 (de) * 2001-05-17 2004-07-15 Immunex Corp., Seattle Therapeutische verwendung von rang-antagonisten
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20040152733A1 (en) * 2002-03-15 2004-08-05 Wallace Owen Brendan Duloxetine for treatment of hot flashes
MXPA05001705A (es) * 2002-08-14 2005-04-19 Pharmacia & Upjohn Co Llc Uso de reboxetina para el tratamiento de sofocos.
KR100748447B1 (ko) * 2002-08-23 2007-08-10 에이에스엠엘 네델란즈 비.브이. 리소그래피 투영장치 및 상기 장치에 사용하기 위한파티클 배리어
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7048210B2 (en) * 2003-05-21 2006-05-23 Frank Clark Showerhead with grooved water release ducts
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047504A2 (en) * 2001-11-29 2003-06-12 Gtx Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
WO2004096259A1 (en) * 2003-04-30 2004-11-11 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
JP2006525306A (ja) * 2003-04-30 2006-11-09 デビオファーム ソシエテ アノニム ゴナドトロピン・ホルモン放出ホルモンを使用する方法及び組成物

Also Published As

Publication number Publication date
EP1796643A1 (en) 2007-06-20
KR20070059167A (ko) 2007-06-11
CN101961327A (zh) 2011-02-02
AU2005287113A1 (en) 2006-03-30
CN101056621B (zh) 2010-11-10
WO2006033979A1 (en) 2006-03-30
BRPI0515668A (pt) 2008-07-29
JP2009029823A (ja) 2009-02-12
EP1796643A4 (en) 2009-09-09
EA014309B1 (ru) 2010-10-29
EP1935415A3 (en) 2009-09-16
IL182091A0 (en) 2011-08-01
AU2005287113B2 (en) 2011-06-16
US20050080143A1 (en) 2005-04-14
CA2581159A1 (en) 2006-03-30
EP1935415A2 (en) 2008-06-25
MX2007003272A (es) 2007-06-05
CN101056621A (zh) 2007-10-17
EA200700690A1 (ru) 2007-10-26

Similar Documents

Publication Publication Date Title
KR100658110B1 (ko) 안드로겐 결핍 유도 골다공증의 예방 및 치료
US10758500B2 (en) Treating androgen deprivation therapy induced hot flashes and bone loss in men using cis-clomiphene
JP2009029823A (ja) アンドロゲン除去によって生じる骨粗鬆症の治療
US20060269611A1 (en) Prevention and treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) Prevention and treatment of androgen—deprivation induced osteoporosis
US20040096510A1 (en) Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) Methods for treating hot flashes
TW200536555A (en) Treating symptoms of androgen deprivation
HK1110015A (en) Treatment of androgen - deprivation induced osteoporosis
HK1134448A (en) Prevention and treatment of androgen-deprivation induced loss of bmd or bone fractures
HK1082198A (en) Prevention and treatment of androgen-deprivation induced diseases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120612